Breast Cancer Clinical Trial
Official title:
Early Detection of Secondary Lymphedema After Cancer Treatments
Many clinical situations in oncologic surgery imply the need to dissect more or less
extensively lymph node stations which are in direct relation with the lymphatic drainage of
the anatomical region affected by cancer.
The dissected lymph nodes drain generally several regions, and their dissection reduces then
the drainage capacity of all these regions, increasing the risk for the patient to develop a
secondary lymphedema, shorter or longer after surgery.
Efficient treatments exist, but are difficult to implement and to continue for a long
time.The later the treatment of the lymphedema begins, the heavier it is, both on the
medical and socio-economic level.
The lymphofluoroscopy, shows that some oncologic patients, operated and free of apparent
secondary lymphedema, present abnormalities of the lymphatic network.
The present study aims to confirm that it is now possible to detect secondary lymphedema at
a subclinical stage.
Many clinical situations in oncologic surgery imply the need to dissect more or less
extensively lymph node stations which are in direct relation with the lymphatic drainage of
the anatomical region affected by cancer.
The dissected lymph nodes drain generally several regions, and their dissection reduces then
the drainage capacity of all these regions, increasing the risk for the patient to develop a
secondary lymphedema, shorter or longer after surgery.
The recent meta-analysis show that nearly 15% of patient operated for a cancer with lymph
node dissection develop after 27 months from surgery a lymphedema of the limb corresponding
to the operated region.
Radio- and chemotherapy may especially encumber the already reduced lymphatic capacity.
The impact on the health and the quality of life of the patient is very significant on the
physical and psychological aspect, but also on social and economic aspect.
Efficient treatments exist, but are difficult to implement and to continue for a long time.
They are considered as serious diseases which are expensive for the INAMI. Lymphedema is a
chronic disease which needs repeated and continued treatments. The later the treatment of
the lymphedema begins, the heavier it is, both on the medical and socio-economic level. Some
patients even lose their job because of their functional infirmity.
Here the investigators remind that lymphedema is painless, even in its most spectacular
cases.
Still currently, a lymphedema is diagnosed after it has developed, and only when the
functional discomfort, or the physical appearance disturb the patient enough to go to
consultation.
The lymphofluoroscopy (new emerging imaging technique in the field of lymphology) used since
3 years by the promoters of the present project, shows that some oncologic patients,
operated and free of apparent secondary lymphedema, present abnormalities of the lymphatic
network. These patients report heaviness sensations or sporadic paraesthesia which generally
does not arouse suspicion of beginning lymphedema.
The present prospective, multidisciplinary and multicentric clinical study aims to confirm
that it is now possible to detect secondary lymphedema at a subclinical stage. In a second
step, prevention will be considered. Detection may be performed using a simple
lymphofluoroscopic examination, which is a minimally invasive and inexpensive imaging
technique. It allows to realize a mapping of the superficial lymphatic network and to
identify the characteristics of the secondary lymphedema in the group of patients at risk to
develop lymphedema after lymph node dissection.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |